Deepa Dharshani Nanayakkara

Deepa Nanayakkara practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Deepa Nanayakkara's NPI, 1629337076, was assigned on May 4, 2012. Deepa Nanayakkara graduated from UNR Med in 2012. Deepa Nanayakkara holds California license A130091.

Deepa Nanayakkara's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Deepa Nanayakkara's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Deepa Nanayakkara to 1 more other site and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Deepa Nanayakkara practices. Vendor and product names are available with a free account.

Infectious disease is Deepa Nanayakkara's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Deepa Nanayakkara is board certified in infectious disease by the American Board of Internal Medicine. Deepa Nanayakkara is licensed in California.

Dmand AI lists cold sores or genital herpes, hiv/aids and pneumonia among the conditions Deepa Nanayakkara treats.

CMS data shows 440 Medicare services from Deepa Nanayakkara across 8 procedure codes in 2024, for 132 Medicare patients. Medicare paid $42,551 for them.

CMS counts 132 Medicare patients who saw Deepa Nanayakkara in 2024. The largest group is 65 to 74, with 71 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 37% are also on Medicaid. Their average risk score is 4.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Deepa Nanayakkara's median patient age at 65, with 44% women.

In 2024, Deepa Nanayakkara wrote 139 Medicare Part D claims for 23 patients. 75% of them were for generic drugs. CMS names the drug for 74 of them, across 5 drugs with 11 or more claims each, at $56,963 in total drug cost. In 2023, CMS named 83 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Deepa Nanayakkara for performance year 2024, reported as part of a group. Deepa Nanayakkara accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Deepa Nanayakkara as offering telehealth.

Dmand AI links 15 papers to Deepa Nanayakkara, published from 2019 to 2024. 2024 was the busiest year, with 3. The most frequent topics are Organ Transplantation, Antibodies, Viral and COVID-19. Deepa Nanayakkara has published most often in Curr Opin Organ Transplant. Deepa Nanayakkara's most frequent co-authors are Sanjeet Singh Dadwal, MD, Randy Allison Taplitz, MD and Alfredo Gonzalo Puing, MD.

CMS Open Payments shows 4 general payments to Deepa Nanayakkara from 3 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 64% of the total. Astellas Pharma US Inc paid the most, $139.

Deepa Nanayakkara graduated from UNR Med in 2012.

Deepa Nanayakkara is in network with 10 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.